Can nanotechnology help develop a workable dengue virus vaccine?
UNC School of Medicine researchers Aravinda de Silva, PhD, professor of microbiology and immunology, and Stefan Metz, PhD, are creating a nanoparticle vaccine that in experiments showed increased antibody responses against one serotype of dengue virus. The de Silva group is collaborating with the UNC laboratories of Chris Luft, PhD, (pharmacy and chemistry), Jenny Ting, PhD, (genetics), and Mike Miley,PhD, (pharmacology), as well as Liquidia Pharmaceuticals to use the same nanoparticle platform to develop a vaccine for all four serotypes of the virus.
UNC researchers discover new target for dengue virus vaccine
By re-engineering a tiny chain of amino acids in one type of dengue virus, Ralph Baric and Aravinda de Silva discover a new path toward solving the dengue vaccine dilemma. The research has the potential to transform vaccine development for other diseases, including SARS and HIV.